Molecular Neuroscience Editors Map Current Progress and Future Challenges

Molecular neuroscience has entered a phase in which the central question is no longer which neurotransmitters allow neurons to communicate, but how molecular processes interact across spatial and temporal scales to shape cellular function, synaptic connectivity, neural circuits and the behavior of the whole organism. That shift frames a new Research Topic in the journal Frontiers in Molecular Neuroscience, introduced by an editorial from Jochen C. Meier of the Technical University Braunschweig, Detlev Boison of Rutgers University, Clive R. Bramham of the University of Bergen, Gregg E. Homanics of the University of Pittsburgh, Jean-Marc Taymans of Univ. Lille, Robert J. Vandenberg of the University of Sydney and Robert J. Harvey of the University of the Sunshine Coast. The collection gathers studies spanning fundamental mechanisms of neuronal and synaptic function, neurodevelopmental and neurodegenerative disorders, and newly emerging therapeutic strategies.

The technological engine behind this transformation is a suite of methods that barely existed a generation ago. CRISPR gene editing, molecular and pharmacological probes, spatiotemporal control of gene expression, optogenetics, induced pluripotent stem cell technology, advanced microscopy and single-cell RNA sequencing now allow researchers to examine differences in the molecular machinery of neurons and glia in unprecedented detail. Yet the editors caution that understanding how these molecular differences produce distinct cellular functions and network behaviors, in health and in disease, remains a daunting task. Greater resolution, they argue, has revealed additional biological heterogeneity and complexity rather than simplifying the picture.

A recurring theme across the collection is that molecular mechanisms must be understood in their specific cellular and functional context. One striking example comes from Chojnacka and colleagues, who investigated auditory hypersensitivity in fragile X syndrome, a neurodevelopmental disorder linked to loss of the fragile X messenger ribonucleoprotein FMRP. Although the mature synapses lacked major ultrastructural abnormalities, the altered postnatal development of these synapses offers a potential mechanistic link between loss of FMRP and the auditory abnormalities characteristic of the syndrome.

At another level of synaptic organization, Gobbo and colleagues examined how neuronal activation relates to synaptic plasticity during the formation of hippocampal memories. Using molecular reporters that track both neuronal activation and postsynaptic potentiation, they showed that the relative weight and spatial distribution of potentiated dendritic spines on hippocampal CA1 neurons differ between memory encoding and memory retrieval. Together, the fragile X and hippocampal studies illustrate how molecular changes at individual synapses can potentially influence processes as different as sensory processing and higher-order cognition.

Ion channels and neurotransmitter receptors form a second pillar of the collection. Deng and colleagues reviewed the contribution of transient receptor potential, or TRP, channels to intracellular calcium dysregulation and neuronal hyperexcitability in epilepsy. The diversity of TRP channel subtypes, and their interplay with intracellular calcium, oxidative stress and other signaling pathways, illustrates both the therapeutic opportunities and the complexities of targeting neuronal ion channels in disease.

Autoimmune neurological disease provides an even sharper lesson in molecular individuality. Wiessler and colleagues studied patients producing autoantibodies against inhibitory glycine receptors, which are key regulators of synaptic inhibition in the spinal cord and brainstem. Their findings revealed considerable patient-specific heterogeneity in which GlyR subunits the autoantibodies recognize, with some antibodies binding epitopes across multiple subunits, alpha 1 through 3 and beta. That pattern complicates the identification of a universal neutralizing epitope and highlights a core challenge for precision medicine: even when the molecular target is known, individual differences in how the target is attacked may demand personalized therapeutic approaches.

Several contributions warn against inferring molecular function from gene or protein expression alone. Despite detecting TH expression, their findings indicate that the TH protein in this nucleus does not show the enzymatic activity required for L-DOPA synthesis, potentially because of differences in the N-terminal regulatory region of the protein. The study is a pointed reminder that a molecular phenotype must be interrogated functionally, not merely catalogued at the transcript or protein level.

Gene regulation and cellular stress responses add yet another layer of complexity. Mehnert and colleagues investigated microexons, short exonic sequences of three to thirty nucleotides that undergo alternative splicing and have been implicated in several neurodevelopmental disorders, in Parkinson’s disease and spinocerebellar ataxia type 3, using deep RNA sequencing of human postmortem brain tissue. No disease-associated splicing events survived correction for multiple testing, but substantially more microexons were detectable in human brain tissue than in corresponding cellular models, underscoring both the subtlety of post-transcriptional regulation and the limits of extrapolating from simplified cellular systems to human brain. In parallel, Huang and colleagues reviewed activating transcription factor 4, a central component of the neuronal integrated stress response, emphasizing that ATF4 signaling is context-dependent: it can support neuronal homeostasis under some circumstances while contributing to neuroinflammation, ferroptosis and neuronal dysfunction when chronically dysregulated. Therapeutic intervention, they suggest, may require modulating the timing and magnitude of stress signaling rather than simply inhibiting the pathway.

The collection also insists that brain disorders cannot always be understood by studying the brain in isolation. Probiotic interventions are an intriguing way to modify this gut-brain communication, although direct evidence that they modulate human brain microglia remains limited. Tumpa and colleagues extended this perspective by considering interactions between peripheral and central innate and adaptive immunity in Parkinson’s disease.

Finally, two translational reviews connect molecular mechanisms to clinically accessible endpoints. Wen and colleagues reviewed the multifactorial molecular basis of age-related hearing loss, also known as presbycusis, encompassing oxidative stress, inflammation, altered autophagy, cellular senescence, genetic susceptibility and environmental influences, and discussed emerging approaches including gene therapy, regenerative strategies, targeted drug delivery and biomarker-based early intervention, while stressing the substantial challenges of clinical translation. Yan and colleagues integrated molecular pathophysiology with neuroimaging in a review of sepsis-associated encephalopathy, linking blood-brain barrier disruption, neuroinflammation, neurotransmitter imbalance and neuronal and glial injury with measurable imaging phenotypes. Taken together, the editors conclude, future progress will depend not only on identifying new molecular mechanisms but on determining when, where and in which cells these mechanisms operate, how they interact across body organs and systems, and how faithfully cellular and animal models represent human disease, steps they view as essential if molecular neuroscience is to deliver meaningful biomarkers, precision interventions and effective therapies for disorders of the central and peripheral nervous system.

Subject of Research: An editorial introducing a Research Topic on molecular mechanisms of neuronal function and neurological disorders

Article Title: Editorial: Molecular neuroscience: current and future challenges

Article References: Meier, J. C., Boison, D., Bramham, C. R., Homanics, G. E., Taymans, J.-M., Vandenberg, R. J., & Harvey, R. J. (2026). Editorial: Molecular neuroscience: current and future challenges. Frontiers in Molecular Neuroscience, 19, Article 2025299. https://doi.org/10.3389/fnmol.2026.2025299

Image Credits: AI Generated

DOI: 10.3389/fnmol.2026.2025299

Keywords: molecular neuroscience, fragile X syndrome, synaptic plasticity, epilepsy, Parkinson's disease, glycine receptor autoantibodies, microexons, age-related hearing loss, sepsis-associated encephalopathy, gut microbiome, integrated stress response, tyrosine hydroxylase